A Phase IIIb, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Polycythemia Vera (PV)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 25 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ropeginterferon alfa-2b (Primary) ; Aspirin
Indications Polycythaemia vera
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors PharmaEssentia Corporation

Most Recent Events

23 Oct 2024 Planned End Date changed from 28 Dec 2025 to 31 Jul 2025.
23 Oct 2024 Planned primary completion date changed from 11 Jan 2024 to 31 Dec 2024.
25 Jun 2024 According to PharmaEssentia media release, company announced completion of enrollment for this trial which has exceeded the enrollment goal of 100 patients to include 111 patients

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight